Oxford BioMedica raises GBP60 million to fund US expansion

(Alliance News) - Oxford BioMedica PLC on Friday said it has raised GBP60 million through a share placing and subscription to support expansion in the US and boost process productivity.

The Oxford, England-based gene and cell therapy developer placed 12.2 million new shares at GBP4.31 each, alongside a subscription for 1.71 million shares by certain existing shareholders, including Briarwood Chase Management, Novo Holdings and Institut Merieux.

The placing price represents a 1.9% discount to Thursday's close of GBP4.40, with the new shares amounting to 13% of the company's issued share capital prior to the issue.

Shares in the company were up 11% at 488.00 pence in London on Friday afternoon.

Proceeds will fund the expansion of US commercial-scale capacity and improvements to process quality and yields, allowing Oxford BioMedica to meet growing client demand across all clinical phases, including late-stage and commercial supply.

The company welcomed strong support from both existing and new investors, including the Massachusetts Institute of Technology.

By Eva Castanedo, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Oxford Biomedica